Mycophenolate Mofetil 250 mg Capsules
Sponsors
AstraZeneca AB
Conditions
Early-stage (II to IIIB) Non-small Cell Lung CancerResectableUnresectable or Advanced Melanoma
Phase 2
A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition
Active, not recruitingCTIS2024-512378-91-00
Start: 2022-06-24Target: 205Updated: 2025-06-16
A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)
RecruitingCTIS2023-508852-21-00
Start: 2022-06-10Target: 493Updated: 2025-08-01